Wolf Group Capital Advisors Sells 3,148 Shares of Eli Lilly and Company (NYSE:LLY)

Wolf Group Capital Advisors decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 57.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,292 shares of the company's stock after selling 3,148 shares during the quarter. Wolf Group Capital Advisors' holdings in Eli Lilly and Company were worth $1,893,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company in the fourth quarter worth approximately $43,000. FPC Investment Advisory Inc. grew its position in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after buying an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $48,000. Highline Wealth Partners LLC grew its position in Eli Lilly and Company by 53.3% during the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock worth $57,000 after purchasing an additional 24 shares in the last quarter. Finally, Capital A Wealth Management LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $63,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on LLY. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, June 7th. Finally, UBS Group lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,011.37.

Eli Lilly and Company Stock Down 0.9%

NYSE:LLY traded down $6.96 during trading hours on Thursday, reaching $784.28. The company's stock had a trading volume of 2,441,727 shares, compared to its average volume of 3,656,357. The company has a market cap of $743.29 billion, a price-to-earnings ratio of 63.81, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The business's 50-day moving average is $778.55 and its 200-day moving average is $801.58. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.58 earnings per share. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.